Estrogen receptors are expressed in several brain areas of various animal species, and steroid hor mones exert physiologic and biochemical effects on the central nervous system. The aim of the present study was to evaluate in female adult rats, the suitability of 16(Xe8P]fluoro-17�-estradiol ([18F]FES), a selective es trogen receptor ligand, for the in vivo assessment of brain estrogen receptors. This was considered to be a prelimi nary step in evaluating the potential usefulness of e8p]PES for studies of cerebral estrogen receptors with positron emission tomography (PET) in nonhuman pri mates and human subjects. We evaluated (a) the time course of the metabolic degradation of [18p]PES in blood; (b) the time course of distribution of the tracer in discrete cerebral areas; (c) the inhibitory effect of increasing doses Estradiol exerts many physiologic effects on the central nervous system including neuronal growth and differentiation (Gould et al., 1990; Koch and Ehret 1989) , changes in cerebral metabolism (Neh lig et aI. , 1985), modulation of neurotransmitters and enzymes (Clarke and Mazyani, 1990; Toran Allerand et al., 1992; Weiland and Wise, 1990) , and the display of sexual, affective, and cognitive be haviors (McEwen, 1981 (McEwen, , 1988 Maggi and Perez, 1985) . The expression of estrogen receptors in sev-Abbreviations used: FES, fluoroestradiol; HPLC, high· performance liquid chromatography; PET, positron emission to mography; RBC, red blood cell.
Summary: Estrogen receptors are expressed in several brain areas of various animal species, and steroid hor mones exert physiologic and biochemical effects on the central nervous system. The aim of the present study was to evaluate in female adult rats, the suitability of 16(Xe8P]fluoro-17�-estradiol ([18F]FES), a selective es trogen receptor ligand, for the in vivo assessment of brain estrogen receptors. This was considered to be a prelimi nary step in evaluating the potential usefulness of e8p]PES for studies of cerebral estrogen receptors with positron emission tomography (PET) in nonhuman pri mates and human subjects. We evaluated (a) the time course of the metabolic degradation of [18p]PES in blood; (b) the time course of distribution of the tracer in discrete cerebral areas; (c) the inhibitory effect of increasing doses Estradiol exerts many physiologic effects on the central nervous system including neuronal growth and differentiation (Gould et al., 1990; Koch and Ehret 1989) , changes in cerebral metabolism (Neh lig et aI. , 1985) , modulation of neurotransmitters and enzymes (Clarke and Mazyani, 1990; Toran Allerand et al., 1992; Weiland and Wise, 1990) , and the display of sexual, affective, and cognitive be haviors (McEwen, 1981 (McEwen, , 1988 Maggi and Perez, 1985) . The expression of estrogen receptors in sev-of cold estradiol on cerebral e8p]PES uptake; and (d) the possibility of in vivo quantification of estrogen receptor binding parameters using both equilibrium and dynamic kinetic analyses. We quantified e8p]PES binding to es trogen receptors using both equilibrium and dynamic ki netic analyses. The results of this study indicate that [18p]PES is a suitable tracer for the measurement of es trogen receptors in the pituitary and hypothalamus, using either the equilibrium or the kinetic analysis. However, [18F]FES is inadequate for the in vivo investigation of estrogen binding sites in brain areas with low receptor density, such as the hippocampus. Key Words: Hormone receptors-Brain-Estradiol-Imaging agents-Pitu itary-Hypothalamus. eral brain areas of various animal species has been demonstrated by in vitro studies with radioactively labelled estradiol or monoclonal antibodies (Balth azart et al. , 1989; Don Carlos et aI. , 1991; Koch and Ehret, 1989) ; high estradiol receptor levels have been described in the anterior pituitary, moderate concentrations have been found in the septum, hy pothalamus, and amygdala, and low concentrations have been observed in the hippocampus (Pfaff and Keiner, 1973; Stumpf et al., 1975; Lieberburg et aI. , 1980) . The in vivo characterization of brain estro gen receptors is required to clarify their role and the activity of estrogen agonist or antagonist sub stances on the central nervous system. 16aesp]Plu oro-1713-estradiol (esp]PES) is a selective estrogen receptor ligand, with binding affinity equal to 80% of that of estradiol (Kiesewetter et aI., 1984b) , pro posed for the in vivo imaging of primary breast can-cer and metastases with positron emission tomog raphy (PET) McGuire et al., 1991) . A good correlation has been demonstrated between the uptake of eSp]FES, assessed by PET, and the estrogen receptor concentration, deter mined by in vitro analysis, in primary breast tu mors. Preliminary PET studies have shown an ac cumulation of eSp]PES in monkey hypothalamus and a significant alteration of ligand accumulation after ' coinjection with cold estradiol (Welch et al., 1988) . However, basic studies evaluating the suit ability of eSp]PES as ligand for the in vivo study of cerebral estrogen receptors in human subjects and nonhuman primates are still lacking and a more ex tensive analysis of the kinetics of distribution of eSp]PES, as well as of the specificity of its regional cerebral uptake, is missing. The aim of the present study was the in vivo evaluation of the kinetic and pharmacologic properties of eSp]PES in rat brain. This study was considered preliminary to a more extensive analysis of the kinetics of distribution of eSp]PES in nonhuman primates and in human sub jects.
Por this purpose we examined in rats: (a) the time course of the metabolic degradation of eSp]PES in blood; (b) the time course of distribution of the tracer in selected cerebral areas; (c) the inhibitory effect of increasing doses of cold estradiol on the cerebral [ 1 8p]PES uptake; and (d) the possibility of the in vivo quantification of estrogen receptor binding parameters using both equilibrium and dy namic kinetic analyses.
METHODS
Chemicals e8F]FES was synthesized from 3, 16�-bis-trifluoro methylsulfonylestrone that was prepared as previously described (Kiesewetter et aI. , 1984a) in five steps from estrone. No-carrier-added aqueous [18F]fluoride was pro duced by a cyclotron with a ISO(p,n)lsF nuclear reaction. The original procedure was modified by trapping the ac tivity with a Kryptofix 2. 2. 2/potassium carbonate solu tion in a 2.6/1/4. 6 ratio of precursor, K2C03 and Krypto fix, respectively. After nucleophilic displacement, the protected I SF-fluoroestrone was reduced with LiAIH4 at low temperature and the final product purified by high performance liquid chromatography (HPLC). The result ing product was dissolved in 3. 5 ml of saline containing 5% ethanol and passed through a Millipore sterile filter into a sterile vial. The final radiochemical yields varied between 5 and 9% at the end of synthesis (EOS). Quality control analyses were carried out by HPLC analytical system (C I S column, acetonitrile17. 5 mM KH2P04 in wa ter 40/60) utilizing a Beckman 170 radioactivity detector in series with a UV detector at 275 nm. The radiochemical purity was >95% with no UV peak detected. The specific activities of the [lsF]FES obtained in the syntheses in this study were assayed by mass spectrometry using a method J Cereb Blood Flow Metab, Vol, 15, No, 2,1995 previously described (Magni et aI. , 1992) , and ranged be tween 4.3 and 11.1 Ci/fLmol. Sterility was tested by bac teriologic tests, and apyrogenicity was controlled for each preparation by a limulus amebocyte lysate test.
Animals
The experiments were performed on female Sprague Dawley rats weighing 200-225 g. For studies of the sys temic metabolism and kinetics of cerebral uptake of [lsF]FES, polyethylene catheters were inserted into one femoral artery and vein under light halothane anesthesia on the day of the experiments. Two hours were allowed for a complete recovery of the animals from surgery and anesthesia. Animals were killed at the end of the study by decapitation.
Blood clearance
The blood clearance of the tracer was studied in four rats after the intravenous bolus injection of 1-2 mCi (0.038-0.075 fLg) of the tracer in 0.5 ml of saline.
Following the administration of [lsF]FES, timed blood samples were collected through the femoral arterial cath eter in plastic tubes. Samples were collected approxi mately every 30 s during the first 5 min, and then at in creasing intervals up to 60 min. In two of the four ani mals, the time course of the ratio between plasma and whole blood ISF was also assessed in each blood sample.
In vitro RBC/plasma partitioning of [lsp]PES
Two sets of in vitro experiments were performed to evaluate the uptake and the exchangeability of [lsF]FES between red blood cells (RBC) and plasma.
To, evaluate the equilibrium distribution ratio of [18F]FES between RBC and plasma, the time course of the uptake of e8F]FES in RBC was assayed in rat hepa rinized whole blood (hematocrit 46%) initially incubated at 37°C with 1 fLCi of [lsF]FES in a glass tube. Timed samples, 200 fLl each, were taken from the tube over the following 60 min, and RBC and plasma were rapidly sep arated by centrifugation. The radioactivity in each frac tion was measured by a 'Y-counter.
To test whether [lsF]FES is readily exchangeable be tween RBC and plasma, i.e., whether there is trapping of eSF]FES in RBC, heparinized whole blood and [lsF]FES were initially incubated at 37"C for 5 min. RBC and plasma were then separated by centrigation; the plasma radioactivity was measured by 'Y counter, whereas the RBC radioactivity was calculated by subtracting the mea sured plasma radioactivity from the radioactivity in the total blood before centrifugation. The RBC were imme diately reconstituted to the original hematocrit with fresh nonradioactive plasma and reincubated at 37°C for 5 min. This procedure was repeated eight times. The ratio of RBC to plasma radioactivity was calculated for each sam ple.
Systemic metabolism
The systemic metabolism of [lsF]FES was assessed in the same animals used for the assay of the blood clear ance. Metabolites were analyzed by ethanol extraction and HPLC. To evaluate the extraction efficiency of eth anol, blood samples were incubated up to 60 min with [lsF]FES, extracted once with 9 volumes of ethanol, vor texed for 1 min and centrifuged at 1,000 g for 10 min. The extracts and pellets were counted by 'Y counter. The same procedure used to assess the ethanol extraction efficiency was used for the initial analysis of metabolites in blood samples collected at 5, 10, 15, 25, 45, and 60 min follow ing the in vivo administration of the tracer. These samples were further analysed by HPLC with the method of Weissman et al. (1990) with minor modification. In brief:
after radioactivity assay ethanol extracts were mixed with an aliquot of unlabeled FES, used as an internal standard, and concentrated to 200 j.1l under a helium stream. The residues were injected into a HPLC apparatus (C IS col umn, 40% acetonitrile in 7. 5 mM KH2P04 mobile phase, 1 mUmin flow rate) and 20 fractions (I ml each) were collected and counted by a 'Y counter. The in vitro extraction efficiency of [18F)FES from whole blood by ethanol was 95%. Thus, any 18F residue of the ethanol extraction in the blood samples collected during the in vivo experiment was considered to be due to metabolites; therefore, the total fraction of 18F-labeled metabolites in blood was determined by adding the frac tion of IsF activity nonextractable in ethanol and the HPLC-assayed IsF-labeled metabolites, after correction for 95% extraction efficiency, as previously described (Mathias et aI., 1987) .
Distribution of 18 F in rat brain
The distribution of 18F uptake in the brain of rats was assayed at 12, 15, 25, 30, 44, and 80 min (n = 3 at each time point) after the injection of -1-2 mCi of [lsF)FES into a femoral vein, to define the time course of the tracer in brain and the time necessary to achieve a condition of pseudoequilibrium between brain tissue and plasma tracer concentration. Immediately after killing by decap itation, the brains were removed, discrete brain areas (pi tuitary gland, hypothalamus, hippocampus, striatum, and cortex) were dissected out, weighed, and placed in a 'Y counter for radioactivity assay.
To evaluate the specificity of [18F)FES binding to es trogen receptors, the inhibition of CSF)FES uptake was studied by coinjection of radiotracer with different doses of unlabeled estradiol (60,18,1. 8, and 0. 18 j.1g/rat; three rats each dose). The animals were killed 30 min after administration of the radiotracer when a condition of pseudoequilibrium was achieved. Tissue samples were handled as described above.
Analysis of binding parameters
The uptake of radiotracer in each brain area was cal culated as a percentage of the injected dose/g of tissue multipled by kg of body weight [(% I. D. /g tissue) x kgbw).
Two different analyses were carried out to quantify the binding of [lsF)FES to estrogen receptors. The first one was an equilibrium analysis originally derived from in vitro techniques, but currently also used for the in vivo assay of dopamine and benzodiazepine receptors (Pap pata et aI., 1988; Farde et aI. , 1986; Leslie and Bennett, 1987; Mennini and Garattini, 1983) . This analysis pro vides values of receptor density (BmaJ and affinity (Kd).
The second analysis, based on the use of dynamic data is a graphic analysis, developed for reversible ligands (Lo gan et aI. , 1990; Volkow et aI., 1993) , that allows only the evaluation of the ratio BmaJKd' Equilibrium analysis. The equilibrium analysis was car ried out using the data derived from inhibition experi ments with increasing doses of cold estradiol. Brain ra dioactivity concentration was converted to pmol/g of tis sue using a mean value of specific activity of 7.5 ± 3. 2 Ci/j.1mol when the radiotracer was injected alone, and the ratio between mCi of [18F)FES and mmoles of estradiol plus FES when competition experiments were per formed. This was based on the observations that estradiol and unlabeled FES have comparable affinities for estro gen receptors (Kiesewetter et aI. , 1984b) , rapid clearance rates (Katzenellenbogen et aI. , 1983; Larner and Hoch berg, 1985) and appear to be equivalent in vivo competi tors at different doses (Katzenellenbogen et al. 1993) .
Specific binding of [lsF)FES was defined as the differ ence in radioactivity concentration between target tissues and striatum because there is a negligible concentration of estrogen receptors in this area (Maggi et aI. , 1989) . As suming that the distribution volume of nonspecifically bound ligand is the same in the striatum and in the other structures the total striatal concentration was used to es timate the concentration of free ligand in the remaining regions of the brain that were analyzed. The Michaelis Menten equation originally developed for the analysis of enzyme-substrate interaction was used for the calcula tion of Bmax and Kd:
where Bound is the concentration of ligand bound to es trogen receptors, Free is the concentration of unbound 
To detect the presence of cooperative interactions be tween receptor, [IS)FES, and estradiol, the value of Bma x obtained by use of Eq. 1 was utilized in Eq. 3 to generate the Hill plot:
and in regions containing receptors, DV becomes:
where NSR is the region with nonspecific binding, TR is the target region, K] and kz are the plasma to tissue and tissue to plasma transport rate constants, respectively, and NS is the ratio between the association and dissoci ation rate constants for nonspecific binding. Assuming that the ratio between K] and kz is approximately equiv alent in NSR and TR, and that NS is the same in all regions, then
By assuming NS negligible, Eq. 6 becomes (6) and Bmaxf Kd can be calculated from the ratio of DV in the two regions. The graphical analysis was carried out using the aver age time course of radioactivity concentration, of all the animals, in brain and plasma by determining the latter correcting the blood concentration for the presence of metabolites and for the whole-blood/plasma distribution ratio. BmaJKd ratios in each of the brain regions exam ined were obtained by dividing the value of DV of the pituitary, hypothalamus, cortex, and hippocampus by the value of DV in the striatum.
RESULTS

RBClPlasma partitioning of [ 18 p]PES
Rapid uptake and exchange of [lsp]FES across the RBC membranes were found. After 5 min of incubation the RBC/plasma ratio of [SF was 0.37 ± 0.07, and it was constant thereafter. Results from the exchangeability experiments indicate that the uptake in RBC is highly reversible; 65.7 ± 0.26% of the RBC activity (previously equilibrated with eSp]FES) was extracted by one wash with fresh nonradioactive plasma and, after eight washes, <2% of the initial activity remained trapped in RBC. These data indicate that [lsF] FES is freely diffusable between RBC and plasma.
Blood clearance and systemic metabolism
After an intravenous pulse, eSF]FES is rapidly cleared from the blood compartment and undergoes a moderate systemic metabolic transformation. As previously observed (Mathias et aI., 1987) , the eth anol extractable fraction of [SF from blood in vivo decreases with time. The HPLC analysis of blood extracts demonstrates the presence of two radioac tive peaks: a hydrophilic one (retention time 4 min) that corresponds to the metabolized compound, and a lipophilic one (retention time 13 min) that corre sponds to the unmetabolized eSF]FES. Thirty min utes after tracer injection >50% of the blood radio activity was due to the e8F]-labeled metabolites. A biexponential function was fitted to the data of un metabolized [lsF]FES in blood ( Fig. 1) for the pur pose of correcting the measured blood concentra tion of eSF]FES for subsequent use in the graphical analysis. The in vivo plasma to whole blood ratio (p/b), assessed in two animals was stable during the entire period of observation and its value was 1.29 ± 0.11 (mean ± SO).
Assessment of plasma time-activity course
Based on the evidence of in vitro exchangeability of eSF]FES between RBC and plasma, and of a constant in vivo plasma/whole blood ratio, plasma concentration of eSF]FES (Cp) was calculated as: Cb x (p/b), where Cb is the concentration of unme tabolized eSF]FES, and p/b is the in vivo plasmal whole blood ratio of I SF.
Distribution of [ 18 p]FES in rat brain
The time course of eSF]FES uptake in the pitu itary, hypothalamus, hippocampus, striatum, and cortex of rats is shown in Fig. 2 . The greatest ac cumulation of activity was detected in the pituitary gland, whereas intermediate levels were found in the hypothalamus; in the remaining areas (striatum, FES in blood at 5 (n = 3), 10 (n = 2),15 (n = 3),30 (n = 4), 45 (n = 3), and 60 (n = 2) min after tracer injection. The fit of a biexponential function to these data was used to generate the metabolite corrected curve of (8). B: Time course of total 18F and unmetabo lized C8F]FES arterial plasma activity in adult female rats. Values are mean ± SD otthree an imals for each experimental time. cortex and hippocampus) the radioactivity concen tration was low. The time of maximum uptake was between 25 and 30 min after injection in the pitu itary gland and hypothalamus, and in these two ar eas the maximum activities were 0.315 ± 0. 047 and 0.078 ± 0.016 [(% l.D./g tissue) x kgbw], respec tively. A pseudoequilibrium between tissue concen tration and metabolite-corrected plasma concentra tion of radioactivity was achieved at 30 min, and maintained thereafter (Fig. 3A) . The 18F tissue/ plasma ratio assessed at 30 minutes was 46.5 ± 7.8 for the pituitary and 7.75 ± 2.2 for the hypothala mus. The pseudoequilibrium activity in the stria tum, indicative of free ligand, was subtracted from the total activity in the pituitary and hypothalamus to yield the specific uptake, i. e. , the bound tracer in those two regions. The Bound/Free concentration ratio reached plateau values of 13.7 ± 1.87 for the pituitary and 1.84 ± 0.24 for the hypothalamus (Fig.  3B ). The coinjection of increasing doses of cold estra diol reduced the accumulation of eSF]FES in the pituitary and in the hypothalamus in a dose dependent mode, whereas no effect was observed in the hippocampus, striatum, and cortex (Fig. 4) . After the intravenous administration of 60 j.Lg of es tradiol, the radioactivity concentration in the pitu itary and in the hypothalamus was inhibited by 90.8 and 80.9%, respectively, and it was reduced to lev els similar to those found in the striatum.
Analysis of binding parameters
The relation between total uptake of e8F]FES (expressed in pmollg) in two target regions, i. e., pituitary and hypothalamus, and in the striatum, where the activity was assumed to be representa tive of the amount of free ligand versus the dose of cold estradiol is shown in Fig. 5 . The difference between total and free tracer is also shown in Fig. 5 , and indicates a saturable specific binding of e 8 F]FES in the hypothalamus and pituitary.
The plots of specific binding (pmol/g) as a func tion of the concentration of free hormone estimated from that in the striatum, showed a typical satura tion isotherm in pituitary and hypothalamus, whereas the Rosenthal-Scatchard plots, showed a linear trend (correlation coefficient >0.98) (Fig. 6) .
As expected, Bmax was much higher in the pituitary gland (124.01 ± 12.36 pmol/g) than in the hypothal- tained from the equilibrium analysis, and the values found in this manner were similar to those found in the striatum and hippocampus ( Table 2) . The ratios between DV T R and DV N SR allowed us the calcula tion of the values of Bmaxl Kd for pituitary and hy pothalamus. A comparison of BmaxlKd obtained from this analysis and the equilibrium approach is summarized in Table 2 . The results obtained by the two methods are in agreement, indicating that the dynamic approach and inhibition experiments using cold estradiol, and based on the assumption of a state of equilibrium, as well as on the assumption of a kinetic and pharmacologic equivalence of estra diol and eSp]PES, provide the same information.
DISCUSSION
In this study we examined the suitability of eSp]PES for the in vivo quantitative evaluation of estrogen receptors in rat brain, as a preliminary step for its use in PET studies. The rank order of the regional distribution of lSp radioactivity in rat brain after intravenous administration of eSp]PES was in agreement with the regional distribution and with the established density of estrogen receptors. The highest concentration of tracer was achieved in brain areas that are rich in estrogen receptors such as the pituitary gland and the hypothalamus. In con trast, the activity concentration is low in the stria tum and cortex where the concentration of estrogen receptors is negligible (Maggi et aI., 1989) . The lack 
Total binding
Specific binding SD of three rats. B: Difference between total uptake in pituitary and hypothala mus, and free tracer concentration in the striatum. Each point represents the mean ± SD of three rats. The continuous lines represent fitted curves obtained using a hyperbolic plus a straight line function for total uptake in pituitary and hypothala mus; a hyperbolic function for the differ ence between total uptake in pituitary and hypothalamus, and free tracer concentra tion in the striatum; and a straight line for the total activity in the striatum. In both areas free ligand concentration was calculated as the difference between total uptake and uptake in the striatum. Each point represents the mean ± SD of three rats.
of tracer retention observed in the hippocampus can be explained by the low receptor concentration demonstrated by in vitro hormone binding analysis showing only limited estrogen-binding activity in this area. Intermediate levels of estrogen receptor in the hippocampus have been demonstrated by an immunoenzymatic assay with an the antibody H222 that selectively recognizes the estrogen binding do main (Maggi et aI. , 1989) ; but, in the same study, a low receptor concentration was found with conven tional binding techniques. Another cause for low uptake in the hippocampus might be the heteroge neous distribution of estrogen receptors within this region. As demonstrated by autoradiography, estro gen receptors are mostly expressed in the entorhi nal cortex, dentate gyrus, and subiculum (Loy et aI., 1988) . This widespread distribution may pro duce a signal-to-noise ratio that is not high enough for the sensitivity of the method used. The absence or low concentration of estrogen re-ceptors in the striatum suggested that this region could be used as the reference area for the evalua tion of free and nonspecifically bound ligand con centration. A state of pseudoequilibrium between specifi cally bound and free ligand, and between free ligand and unmetabolized [lsF]FES concentration in plasma, was observed at 30 min. This observation suggested quantitation of estrogen receptor binding with a saturation equilibrium analysis. For this pur pose we carried out inhibition experiments at 30 min after tracer injection using cold estradiol as dis placer. The use of estradiol allowed us to demon strate the specificity of eSF]FES binding to estro gen receptors and to transform inhibition curves into saturation curves based on the previously re ported assumption of pharmacologic and kinetic equivalence of FES and estradiol. The inhibition experiments showed a dose-dependent displace ment of [lsF]FES; at the higher doses of estradiol the concentration in the pituitary and hypothalamus is similar to that in the striatum and hippocampus. The plot of the total concentration of ligand in tis sues versus the dose of estradiol, showed in the striatum a linear relation between the injected dose and the uptake of eSF]FES. In the pituitary and hypothalamus the tracer uptake rose rapidly with low doses, and then became linear and parallel to the striatal concentration. The subtraction of the striatal lsF concentration from the total lsF concen tration in pituitary and hypothalamus demonstrated a saturation of the tracer uptake with increasing concentrations of estradiol. This observation fur ther supports the use of the striatum as the refer ence region for the estimation of the free ligand con centration, assuming negligible amounts of nonspe cific binding. This in turn led to a saturation curve of specifically bound ligand as a function of the free ligand concentration and the Rosenthal-Scatchard plot with the features of a typical ligand-receptor interaction. These observations supported the hy pothesis that the tracer uptake in pituitary and hy pothalamus was not due to diffusion phenomena or to nonspecific binding to tissular constituents, but to a process depending upon the interaction of the tracer with free estrogen receptors. This observa tion provided the basis for the in vivo quantitative measurement of both Bmax and Kd. In a previous study (Katzenellenbogen et aI., 1993) in which eSF]FES and estradiol were used in a similar satu ration analysis of estrogen receptor binding in uterus and ovaries (esF]FES as radioligand and es tradiol as cold displacer), the authors observed a nonlinear uptake/dose relative to eSF]FES uptake (Scatchard-like plot) at low doses of estradiol in these two regions with high levels of estrogen re ceptors. The explanation provided was that at low doses of ligand the uptake of the tracer, in regions with high levels of estrogen receptors, was limited by flow or by tissue permeability. The same au-thors, who performed their analysis without sub traction of either nonspecific binding or free ligand concentration, showed a saturation of tracer uptake in the ovaries and uterus. In the present study, we found a linear relation in the Scatchard plot at all doses of estradiol, and a saturation of tissue uptake only when striatal concentration was subtracted from total uptake. The reason for this apparent dis crepancy might be a different behavior of the tracer in the two series of anatomic region considered. The equilibrium approach and a dynamic analy sis, based on the assessment of the time course of [lsF]FES radioactivity concentration in plasma and tissue, were also compared. In the dynamic analy sis, as in the equilibrium analysis, the striatum was used as the reference region, and the nonspecific binding was assumed to be negligible.
The results of the equilibrium approach and the dynamic analysis were in agreement and provided comparable values of Bmax l Kd ratios, i.e. , the satu ration experiments, in which a state of equilibrium was assumed and cold estradiol was used as dis placer, provided information similar to that ob tained by the evaluation of the kinetic behavior of a The distribution volume is determined as the slope of the line fitted to the graph of fT;Ct(t)dtICtCD vs. fT;Cp(t)dtICtCD for ex perimental times T> t'. where t' is the time at which equilibrium is achieved. In regions devoid of receptors the slope is equal to K,lk2 * (1 + NS), for regions containing receptors the slope is equal to K,lk2 * [1 + NS + (BmaxIKd)]'
b Values are the estimate ± standard errors of the estimates from fitting the data from three animals at each time point.
found by in vitro experiments, and the Kd values 2-3-fold higher (Lieberburg et a!. , 1980) . However, the ratio between pituitary and hypothalamic recep tor densities was within the order of magnitude of that previously estimated by in vitro techniques us ing 3H -labeled estradiol (Lieberburg et a!. , 1980) . A similar overestimation of the in vivo estrogen recep tor binding capacity of [ 1 8F]FES, was also found for the uterus and ovaries (Katzenellenbogen et aI. , 1993) .
On the other hand, in vitro and in vivo results of estrogen receptor binding are difficult to compare: most in vitro measurements are performed on par tially purified estrogen receptors obtained from ei ther the cytosolic or the nuclear extracts, whereas in vivo studies are influenced by several cellular and biochemical variables. Moreover, in vivo, the tracer can bind not only with nuclear or cytosolic receptors, that are usually measured by in vitro techniques, but also on receptors localized on the rough endoplasmic reticulum, dendrites, and axon terminals (Blaustein et a!., 1992) . Whether these lat ter binding sites are functional receptors or repre sent only a site of synthesis of estrogen receptors, remains to be demonstrated. However, these sites could interact with the tracer and thus explain the high binding capacity found in this study.
For both analyses, we assumed that the nonspe cific binding was negligible, but the presence of nonspecific binding could cause errors in the esti mate of Kd and BmaxlKd' Indeed, in vitro experi ments report different amounts of nonspecific bind ing, depending on the technique used, viz. , nuclear versus cytoplasmatic analysis, isolated cells or whole tissues. A partition coefficient (K 1 lk2) higher than unity suggests a higher distribution of the tracer in brain than in plasma, possibly resulting from nonspecific binding.
For tracers with passive diffusion across capillar-ies it is possible to infer the amount of nonspecific binding by assuming that the concentration of free tracer in tissue water is equal to the concentration of free tracer in plasma water (Kawai et a!., 1991) . In order to define the fraction of estradiol in plasma equilibrating with tissues, some considerations are necessary. More than 95% of estradiol is bound to plasma proteins, including seroalbumin and also to afetoprotein during the first month of life and in pregnancy; both free and albumin-bound estradiol is taken up by peripheral tissues, such as uterus and ovaries (Kelner et a!. , 1982) . Therefore, we can as sume that both bound and free estradiol are freely taken up by the pituitary. Moreover, Pardridge et al. (1979) demonstrated that both free and albumin bound estradiol permeate the blood-brain barrier (BBB). By assuming that the free concentration of tracer in plasma is equal to the free concentration of tracer in tissue, it is possible to estimate the free fraction of tracer in brain using the DV NSB of the tracer in the striatum, found to be 1.15. The DVNSB obtained in the present analysis is equal to the equilibrium distribution ratio between the sum of free and non specifically bound tracer in the striatum, and that in plasma. In tissues inside the BBB, if one were to assume that only the fraction of the tracer in plasma that is riot bound to plasma albumin equilibrates with the tissue, then the free fraction of tracer in tissue estimated from the DV NSB would be 4% of the total tissue concentration (95% of estradiol is bound to plasma proteins). This would produce an overestimation of 96% in Kd values and differences between the estimated free fraction of tracer in tis sues inside and outside the BBB. On the other hand, if one were to assume that the total concen tration of eSF]FES in the plasma is equal to the a All the parameters are calculated assuming that the radioac tivity in the striatum corresponds to the free tracer concentration and that the nonspecific binding is negligible.
b K,lk2 ratios determined by substituting the BmaxlKd values obtained from the equilibrium analysis in Eq. (5) (see text). c K,lk2 ratios calculated by Eq. (4) (see text). concentration of free tracer in tissue (in regions with or without the BBB), then the free fraction of tracer in tissue estimated from the DV NSB equals 87% [(1/1.15) x 100] of the total. This means an overestimation of 13% in the Kd values and an un derestimation of 13% in BmaxlKd. The finding of Pardridge et al. (1979) that both free and albumin bound estradiol permeate the BBB supports the lat ter hypothesis that the concentration of [lsp]PES in plasma equilibrates with the free tracer in the tis sue. This correction for nonspecific binding might be inappropriate, however, because it does not take into acount the amount of free ligand possibly ac cumulated in cerebral intracellular and/or extracel lular spaces, and freely interacting with estrogen receptors that are located in the cytosol as well as in the nucleus and neuronal terminals (Blaustein et aI., 1992) .
The overestimation of binding parameters could also be explained by errors in the estimated specific activity of the tracer caused by different metabolic rates of estradiol and PES. However, the similarity of the results obtained by the graphic analysis, us ing only fluoroestradiol data, and the saturation analysis in which either fluoroestradiol alone or flu oroestradiol plus estradiol were used, indicates that the tracer and the cold ligand have similar systemic and cerebral metabolic degradation. Kato and Villee (1967) reported that in adult female rats 4 to 16% of estradiol is converted, in brain region devoid of receptors, into metabolites more polar than es tradiol itself, whereas in the pituitary gland and hy pothalamus the amount of metabolites ranges from 2 to 13%, depending on the region examined (ante rior vs. posterior regions of pituitary and hypothal amus). King et al. (1965) reported negligible amounts of estradiol metabolites in the pituitary gland and uterus. Such data are in agreement with those on fluoroestradiol reported by Van Brocklin et al. (1992 in estrogen receptor-rich regions, such as uterus and ovaries, indicating that in pitu itary and hypothalamus the percentage of fluo roestradiol or estradiol metabolites is negligible and does not affect the estimation of binding parame ters. However, lack of consideration of the pres ence of up to 16% of hydrophilic metabolites in brain regions devoid of receptors, may cause a pro portional overestimation of Kd and underestimation of BmaxlKd.
All the experiments were performed in female adult nonovariectomized rats. This experimental condition was chosen because it is closer to the physiologic situation in which the circulating hor mone competes with the tracer. In the experiments performed with loading doses of estradiol, the effect J Cereb Blood Flow Metab. Vol. 15, No.2, 1995 of circulating hormone in producing a variability of data, is overcome by the levels of exogenous estra diol. In fact, during the estrous cycle, estrogen lev els vary from 21 pg/ml in estrus to 68 pg/ml in pro estrus (Nehlig et al., 1985) , whereas the lowest dose of estradiol used in this study produces estrogen levels of 106.2 pg/ml, almost twice the level in blood during proestrus. In the experiments with tracer concentration of [lsp]PES, the endogenous estra diol may produce significant variability in tracer up take (McElvany et aI., 1983) , and the concentration of circulating hormone should be taken into account in order to reduce variability in tracer uptake. Moreover, the presence of considerable amounts of endogenous estradiol in tissue may produce an in crease in Kd and thus a decrease in the estimates of BmaxlKd'
In conclusion, we have demonstrated that [lsp]PES is a suitable tracer for the visualization and the in vivo quantification of estrogen receptors in the pi tuitary and hypothalamus using either an equilib rium or a dynamic approach. However, eSp]PES seems to be inadequate for the in vivo investigation of estrogen binding sites in brain areas that have low receptor levels such as the hippocampus.
Although the graphic analysis does not allow the determination of Bmax and Kd, but only Bma)Kd' it appears to be suitable for dynamic PET studies. In contrast, the saturation analysis requires several studies using different doses of cold estradiol, but provides the possibility of assessing both Bmax and Kd· However, the estimate of both Kd and BmaxlKd with both analyses are affected by the presence of nonspecific binding that because of the subcellular distribution of estrogen receptors could not be ac curately evaluated. Therefore, considerable uncer tainty still remains in the in vivo estimate of [lsp]PES affinity.
